Molecular Partners (MOLN) vs Outlook Therapeutics (OTLK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Molecular Partners (MOLN) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 37.5% versus a loss of 79.3%. Over five years, MOLN leads with a -77.9% price change compared with -98.6% for OTLK. Molecular Partners is the larger company by market cap ($96.8 million vs $94.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | OTLK |
|---|---|---|
| Share price | $2.53 | $0.39 |
| Market cap | $96.80M | $94.94M |
| 1-day change | -5.25% | -2.74% |
| YTD return | -42.07% | -75.32% |
| 1-year return | -37.50% | -79.26% |
| 5-year return | -77.87% | -98.58% |
| EPS (TTM) | $-1.68 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.41M |
| Net income (latest FY) | — | $-62.42M |
| Gross margin | — | 4.05% |
| Operating margin | — | -4744.25% |
| Net margin | — | -4416.22% |
| 52-week high | $5.36 | $2.54 |
| 52-week low | $2.52 | $0.161 |
| Distance from 52-week high | -52.89% | -84.63% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +295.64% | +1189.74% |
| Average volume | 1.63K | 4.60M |
| Shares outstanding | 38.34M | 243.45M |
| Employees | 134 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed OTLK by 41.8 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
MOLN vs OTLK FAQ
Which is bigger, Molecular Partners or Outlook Therapeutics?
Molecular Partners (MOLN) is larger, with a market capitalization of $96.80M compared with $94.94M for Outlook Therapeutics (OTLK).
Which stock has performed better over the past year, MOLN or OTLK?
MOLN returned -37.50% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Outlook Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.